Opinion

Video

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

Author(s):

Jack R. Andrews, MD,Eugene B. Cone, MD

Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.

Timecodes

1:35 Individualized Care for PC

9:24 Frailty & Comorbidities in PC

12:27 Molecular Testing in PC

18:10 Sequencing in PC

22:00 Doublets/Triplets in mHSPC

30:00 Subgroups in mHSPC

39:00 ARASENS Subgroup Analysis

43:55 Future of mHSPC Care

Related Videos
Checkpoint Inhibitors for Treatment of NMIBC
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Communication of Treatment Options for High-Risk NMIBC
3 experts are featured in this series.
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
1 expert in this video
BPH: The Patient Journey
Addressing Remaining Unmet Needs in mCRPC
Addressing Remaining Unmet Needs in mCRPC
Use and Sequencing of Novel Treatments in NMIBC
Use and Sequencing of Novel Treatments in NMIBC
The DORA Trial
The DORA Trial
FDA-Approved Treatments for BCG-Unresponsive NMIBC
FDA-Approved Treatments for BCG-Unresponsive NMIBC
Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
Clinical Perspectives on Early Use of RAD-ENZ
Clinical Perspectives on Early Use of RAD-ENZ
Related Content
US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
doctor holding a pen talking to patient
December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke
“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Doctor discusses treatment information with patient
October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke
Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
First European patient treated for urethral stricture with novel drug-coated balloon catheter
February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick
The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.
© 2025 MJH Life Sciences

All rights reserved.